Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Syndax Pharmaceuticals Inc | sndx-ex321_6.htm |
| EX-31.2 - EX-31.2 - Syndax Pharmaceuticals Inc | sndx-ex312_10.htm |
| EX-31.1 - EX-31.1 - Syndax Pharmaceuticals Inc | sndx-ex311_8.htm |
| EX-10.14 - EX-10.14 - Syndax Pharmaceuticals Inc | sndx-ex1014_191.htm |
| 10-K - 10-K - Syndax Pharmaceuticals Inc | sndx-10k_20201231.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement Nos. 333-210412, 333-220172, 333-226678, 333-233083, and 333-241654 on Form S-8 and Registration Statement No. 333-233564 on Form S-3 of our report dated March 11, 2021, relating to the financial statements of Syndax Pharmaceuticals, Inc. and subsidiaries appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 11, 2021